Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29858318 | 1.00 | CHRM2 (0.49) | CHRM2ADRA2ATSHRTDP1ALDH1A1 | |
| SCHEMBL19565413 | 0.84 | KDM1A (0.47) | CHRM2ALDH1A1LMNAHTR2AKDM1A | |
| SCHEMBL5740020 | 0.81 | HTR2A (0.48) | CHRM2ADRA2ATSHRTDP1ALDH1A1 | |
| SCHEMBL4231166 | 0.80 | CHRM2 (0.47) | CHRM2ADRA2ATSHRTDP1ALDH1A1 | |
| SCHEMBL14358172 | 0.80 | CHRM2 (0.47) | CHRM2ADRA2ATSHRTDP1ALDH1A1 | |
| SCHEMBL29734668 | 0.77 | CHRM2 (0.44) | CHRM2ADRA2ATSHRTDP1ALDH1A1 | |
| SCHEMBL18440340 | 0.75 | CHRM2 (0.42) | CHRM2HTR2AKDM1AMAPK1SMN1; SMN2 | |
| SCHEMBL7070214 | 0.75 | CHRM2 (0.42) | CHRM2ADRA2ATSHRTDP1ALDH1A1 | |
| SCHEMBL30097085 | 0.75 | CHRM2 (0.42) | CHRM2ADRA2ATSHRTDP1ALDH1A1 | |
| SCHEMBL27375579 | 0.75 | CHRM2 (0.42) | CHRM2ADRA2ATSHRTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2023-02-23 | — | — | US | disclosed |
| EP-3328835-B1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARM INC (US) | 2022-10-12 | — | — | EP | disclosed |
| CN-111699220-B | Squarylium salt compound for display device | 日东电工株式会社 | 2022-08-23 | — | — | CN | disclosed |
| US-11422403-B2 | Squarylium compounds for use in display devices | NITTO DENKO CORPORATION (JP) | 2022-08-23 | — | — | US | disclosed |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | ARENA PHARMACEUTICALS, INC. (US) | 2022-07-26 | — | — | US | disclosed |
| CN-108137508-B | 5-HT2CReceptor agonists and compositions and methods of use | 艾尼纳制药公司 | 2021-08-27 | — | — | CN | disclosed |
| US-20200383993-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200383993-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | ARENA PHARMACEUTICALS, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200369889-A1 | SQUARYLIUM COMPOUNDS FOR USE IN DISPLAY DEVICES | NITTO DENKO CORPORATION (JP) | 2020-11-26 | — | — | US | disclosed |
| EP-2222647-B1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND C-MET INHIBITORS | CEPHALON INC (US) | 2015-08-05 | — | — | EP | disclosed |
| EP-2684874-A1 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and C-met inhibitors | Cephalon, Inc. (US) | 2014-01-15 | — | — | EP | disclosed |
| US-8552186-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-MET inhibitors | CEPHALON, INC. (US) | 2013-10-08 | — | — | US | disclosed |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | CEPHALON, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-8148391-B2 | Fused bicyclic derivatives of 2,4-diaminopyrimidine as ALK and c-Met inhibitors | CEPHALON, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | CEPHALON, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| EP-0856514-B1 | 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives | HOFFMANN LA ROCHE (CH) | 2001-06-13 | — | — | EP | disclosed |
| CN-1049215-C | Process for preparing benzoquinazoline thymidylate synthase inhibitors | WELLOCOME FOUNDATION LTD (GB) | 2000-02-09 | — | — | CN | disclosed |
| EP-0856514-A1 | 8-substituted-1,3,8-triazaspiro[4.5]decan-4-on derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1998-08-05 | — | — | EP | disclosed |
| CN-1058208-A | PHARMACEUTICAL COMPOUNDS | WELLCOME FOUND (GB) | 1992-01-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221555-A1 | FUSED BICYCLIC DERIVATIVES OF 2,4-DIAMINOPYRIMIDINE AS ALK AND c-MET INHIBITORS | ALK, MET, RET | CHRM2 2093/4885ADRA2A 2163/4885TSHR 1728/4885 |
| US-11422403-B2 | Squarylium compounds for use in display devices | SQLE, SPR, SYMPK | CHRM2 1087/4885ADRA2A 1758/4885TSHR 4154/4885 |
| US-20230055376-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | CHRM2 130/4885ADRA2A 26/4885TSHR 148/4885 |
| US-20200383993-A1 | 5-HT2C RECEPTOR AGONISTS AND COMPOSITIONS AND METHODS OF USE | HTR2C, HTR2A, HCRTR2 | CHRM2 130/4885ADRA2A 26/4885TSHR 148/4885 |
| US-11395824-B2 | 5-HT2C receptor agonists and compositions and methods of use | HTR2C, HTR2A, HCRTR2 | CHRM2 130/4885ADRA2A 26/4885TSHR 148/4885 |
| US-20120165519-A1 | Fused Bicyclic Derivatives of 2,4-Diaminopyrimidine as ALK and c-MET Inhibitors | ALK, MET, RET | CHRM2 2093/4885ADRA2A 2163/4885TSHR 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.